NEW ORLEANS, LA—Adding the factor XIa inhibitor asundexian (Bayer) to antiplatelet therapy tops antiplatelet therapy alone ...

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

A 26% relative hazard reduction in recurrent ischemic stroke was observed (HR 0.74), with primary efficacy assessed as time to first ischemic stroke. OCEANIC-STROKE trial data show asundexian cuts ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

Study findings suggest the therapeutic window for DAPT benefit may extend up to 42 hours, but risk increases after 72 hours.

International Stroke Conference; Feb. 4-6, 2026; New Orleans. A prior history of ischemic stroke may signal higher risk for another stroke during pregnancy and in the early postpartum period, ...

FRANKFURT, Feb 5 (Reuters) - Bayer said on Thursday its experimental blood thinner cut the risk of stroke recurrence by 26% ...

Indian data reveals up to 20% of stroke patients experience recurrence, underscoring the need for improved long-term care.

The National Institutes of Health (NIH) on Tuesday discontinued the low-dose rivaroxaban arm of its ongoing Phase 3 CAPTIVA ...

Even larger effects were seen for hemorrhagic stroke with a relative reduction of 30%. HealthDay News — Salt substitution is safe and reduces the risk for stroke recurrence and death among patients ...

Heart-rending cases like that of Steven Spence — a 68-year-old man who suffered a second stroke in his home only hours after being treated for his first one in a hospital — underscore the urgent need ...

Cryptogenic stroke survivors who went on to get an insertable cardiac monitor (ICM) had a similar risk of recurrent stroke whether or not any atrial fibrillation (Afib, AF) ever turned up on ...